Physician profile
Benjamin Cox
NPI 1861248510
$4,037.85
in general payments reported to CMS, 2019-2025
28 companies · $2,941 in 2025
The $2,941 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,097 · 2025: $2,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,037.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.57 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $410.47 | 2025 | |
| Pfizer INC. | $301.50 | 2025 | |
| Axsome Therapeutics, INC. | $253.46 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $247.66 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $211.94 | 2024-2025 | Rexulti |
| Antares Pharma, INC. | $175.22 | 2024-2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $170.93 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $165.47 | 2024-2025 | Veozah |
| Lilly USA, LLC | $146.80 | 2024-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $143.69 | 2024-2025 | Trintellix |
| Dexcom, INC. | $130.52 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $120.58 | 2024 | Arexvy |
| Gilead Sciences, INC. | $110.53 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.92 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $90.76 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $63.13 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $61.98 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.86 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $46.56 | 2024-2025 | Saxenda, Wegovy, Ozempic |
| Sumitomo Pharma America, INC. | $43.69 | 2024-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $25.91 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.99 | 2025 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $21.95 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $19.28 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $17.59 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $15.32 | 2024 | Uzedy |
| Exact Sciences Corporation | $14.57 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.